CliffBio

Otsuka Pharmaceutical

Patent cliffs & loss of exclusivity

Otsuka Pharmaceutical Co., Ltd. is a Japanese pharmaceutical and nutraceutical company established on August 10, 1964, with its head office in Chiyoda, Tokyo. It researches, develops, manufactures and sells medicines, clinical testing equipment, medical devices, foods and cosmetics. It is a wholly owned subsidiary of Otsuka Holdings.

Company

Also Known AsOtsuka
AngelList URLhttps://angel.co/otsuka-pharmaceutical
Legal NameOtsuka Pharmaceutical Co., Ltd.
Company Operating StatusActive
Crunchbase URLhttps://www.crunchbase.com/organization/otsuka-pharmaceuticals
Full Address3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka 540-0021, Japan
Instagram URLhttps://www.instagram.com/otsukanc/
Legal Entity Identifier353800T027BNMJ8BG858

34 upcoming patent cliffs

DrugIngredientTypeCliff
  1. ABILIFYARIPIPRAZOLESmall mol.Mar 2027
  2. ABILIFYARIPIPRAZOLESmall mol.Mar 2027
  3. ABILIFYARIPIPRAZOLESmall mol.Mar 2027
  4. ABILIFYARIPIPRAZOLESmall mol.Mar 2027
  5. ABILIFYARIPIPRAZOLESmall mol.Mar 2027
  6. ABILIFYARIPIPRAZOLESmall mol.Mar 2027
  7. ABILIFYARIPIPRAZOLESmall mol.Mar 2027
  8. ABILIFYARIPIPRAZOLESmall mol.Mar 2027
  9. REXULTIBREXPIPRAZOLESmall mol.Jun 2029
  10. JYNARQUETOLVAPTANSmall mol.Apr 2030
  11. JYNARQUETOLVAPTANSmall mol.Apr 2030
  12. JYNARQUETOLVAPTANSmall mol.Apr 2030
  13. JYNARQUETOLVAPTANSmall mol.Apr 2030
  14. JYNARQUETOLVAPTANSmall mol.Apr 2030
  15. SAMSCATOLVAPTANSmall mol.Apr 2030
  16. SAMSCATOLVAPTANSmall mol.Apr 2030
  17. SAMSCATOLVAPTANSmall mol.Apr 2030
  18. REXULTIBREXPIPRAZOLESmall mol.Apr 2033
  19. REXULTIBREXPIPRAZOLESmall mol.Apr 2033
  20. REXULTIBREXPIPRAZOLESmall mol.Apr 2033
  21. REXULTIBREXPIPRAZOLESmall mol.Apr 2033
  22. REXULTIBREXPIPRAZOLESmall mol.Apr 2033
  23. ABILIFY ASIMTUFIIARIPIPRAZOLESmall mol.Apr 2033
  24. ABILIFY ASIMTUFIIARIPIPRAZOLESmall mol.Apr 2033
  25. ABILIFY MYCITE KITARIPIPRAZOLESmall mol.Oct 2033
  26. ABILIFY MYCITE KITARIPIPRAZOLESmall mol.Oct 2033
  27. ABILIFY MYCITE KITARIPIPRAZOLESmall mol.Oct 2033
  28. ABILIFY MYCITE KITARIPIPRAZOLESmall mol.Oct 2033
  29. ABILIFY MYCITE KITARIPIPRAZOLESmall mol.Oct 2033
  30. ABILIFY MYCITE KITARIPIPRAZOLESmall mol.Oct 2033
  31. ABILIFY MAINTENA KITARIPIPRAZOLESmall mol.Apr 2041
  32. ABILIFY MAINTENA KITARIPIPRAZOLESmall mol.Apr 2041
  33. ABILIFY MAINTENA KITARIPIPRAZOLESmall mol.Apr 2041
  34. ABILIFY MAINTENA KITARIPIPRAZOLESmall mol.Apr 2041
  35. FERRISELTZFERRIC AMMONIUM CITRATESmall mol.—
  36. BUSULFEXBUSULFANSmall mol.—
  37. ABILIFYARIPIPRAZOLESmall mol.—
  38. DACOGENDECITABINESmall mol.—
  39. ABILIFYARIPIPRAZOLESmall mol.—
  40. ABILIFYARIPIPRAZOLESmall mol.—
  41. PLETALCILOSTAZOLSmall mol.—
  42. PLETALCILOSTAZOLSmall mol.—
  43. RAXARGREPAFLOXACIN HYDROCHLORIDESmall mol.—
  44. RAXARGREPAFLOXACIN HYDROCHLORIDESmall mol.—
  45. RAXARGREPAFLOXACIN HYDROCHLORIDESmall mol.—

Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.